• In the second quarter of 2026, Agios Pharmaceuticals, Inc. reported revenue of US$44.75 million versus US$12.46 million a year earlier, with net loss decreasing from US$112.02 million to US$100.70 million and basic loss per share from continuing operations improving from US$1.93 to US$1.69.
• Over the first six months of 2026, revenue rose to US$65.49 million from US$21.18 million while net loss and loss per share narrowed only slightly, underscoring how higher sales are beginning to ease, but not yet resolve, the company’s substantial losses.
• Next, we’ll assess how this sharp year-over-year revenue increase, alongside a slightly smaller net loss, affects Agios Pharmaceuticals’ existing investment narrative.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Agios Pharmaceuticals Investment Narrative Recap

To own Agios today, you have to believe PYRUKYND can anchor a broader rare-disease franchise while the company steadily narrows its heavy losses. The sharp Q2 2026 revenue jump to US$44.75 million offers some evidence that recent approvals and launches are gaining traction, but the six‑month net loss of US$199.81 million underlines that cash burn and execution on new indications remain the key near term catalyst and the most immediate risk.

The most relevant recent announcement here is the FDA’s Priority Review of mitapivat (PYRUKYND) for sickle cell disease, with a PDUFA date of November 1, 2026. This filing sits at the heart of the investment case, as success could extend PYRUKYND beyond its current rare anemia indications and help justify the current spending levels that are still driving sizeable quarterly losses, even as revenue rises.

Yet, against this progress, investors should also be aware that...

Agios Pharmaceuticals' narrative projects $485.0 million revenue and $82.4 million earnings by 2029.

Uncover how Agios Pharmaceuticals' forecasts yield a $44.00 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Some of the lowest‑estimate analysts were already assuming very fast revenue growth of about 72.5% a year but still no profits, so their more pessimistic view on risk and pricing power could shift further as this latest US$44.75 million quarter is digested.

Explore 2 other fair value estimates on Agios Pharmaceuticals - why the stock might be worth just $44.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Agios Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agios Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.